cardinal health glp-1 receptor agonist weight management diabetes treatments GLP-1 Agonists: Revolutionizing the Treatment of Obesity, but Are They Enough? - Eric Velazquez, MD - Bariatric Surgeon GLP-1-directed NMDA receptor antagonism for

Further work is needed to understand the pathological and physiological role for GLP-1 vs

GLP-1s have already demonstrated a track record of safety and mortality reduction that can benefit a large percentage of the population, many of whom have a substance use disorder

This discovery led to the development of exenatide, which in 2005 became the first GLP-1 receptor agonist approved by the FDA for the treatment of type 2 diabetes (T2DM)

Abstract Aim Obesity is a global epidemic

PubMedPMC 64

It was demonstrated, that metabolic disturbances in hypothalamic astrocytes, caused either by selective knock-out of insulin receptors or decreased generation of reactive oxygen species (ROS) modulated glucose transport via BBB and also led to modification in behavioral responses in experimental animals [95, 96]